---
title: "VK2735 in Chronic weight management: Economic information and modeling report"
description: "Formulary evidence on VK2735 in Chronic weight management: Economic information and modeling report. Covers Cost-effectiveness evidence. 21 evidence topics quoted from 12 sources."
canonical: "https://www.evicenter.com/drugs/vk2735--chronic-weight-management/economics/cost-effectiveness"
published: "2026-11-15T21:45:47-05:00"
modified: "2026-11-15T21:45:47-05:00"
---

# VK2735 in Chronic weight management: Economic information and modeling report

<a id="economic-information-and-modeling-report"></a>

## 4 Economic Information and Modeling Report

<a id="heading-4.1"></a>

### 4.1 Modeling Overview

<a id="topic-4.1-1"></a>

#### Summary

No published cost-effectiveness analysis, budget impact model, or announced price exists for VK2735; the evaluations below describe the incretin-based anti-obesity medications it would join. The ICER final evidence report of December 2025 modeled injectable semaglutide, oral semaglutide (at an assumed price equal to that of injectable semaglutide), and tirzepatide, each added to lifestyle modification, over a lifetime horizon from the health care sector perspective. At annual net prices of $6,829 for semaglutide and $7,973 for tirzepatide, the incremental cost-effectiveness ratios versus lifestyle modification were $57,779 per QALY gained for tirzepatide, $66,355 for injectable semaglutide, and $75,456 for oral semaglutide, and no discount was needed to reach the health benefit price benchmark of any of the three. ICER estimated about 92 million eligible U.S. adults and found that fewer than 1% could be treated within five years before its $880 million annual budget impact threshold was crossed, including at a Medicare price of $245 per month, and issued an access and affordability alert.

Other U.S. analyses reached different conclusions depending on the drug price and the perspective. The ICER 2022 assessment (semaglutide $237,000 per QALY gained) and a 2025 lifetime microsimulation (tirzepatide $197,023 and semaglutide $467,676 per QALY gained) found the GLP-1-based drugs not cost-effective at the net prices then assumed. A 30-year U.S. third-party payer model found semaglutide 2.4 mg cost-effective against all comparators at $150,000 per QALY gained, and a societal-perspective model based on SURMOUNT-5 found tirzepatide less costly and more effective than semaglutide. For Medicare, CBO estimated that authorizing coverage of anti-obesity medications would increase net federal spending by about $35 billion from 2026 to 2034, with a direct federal cost of about $5,600 per user in 2026, and a separate analysis estimated $3.1 billion to $6.1 billion in added annual Part D costs at 5% to 10% uptake among newly eligible beneficiaries. The CMS Medicare GLP-1 Bridge demonstration provides certain GLP-1 drugs to eligible Part D beneficiaries for a $50 copay from July 1, 2026, to December 31, 2027. In 2025, 19% of firms with 200 or more workers, and 43% of firms with 5,000 or more workers, covered GLP-1 agonists for weight loss.

Source: [ICER (2025)](https://icer.org/wp-content/uploads/2025/12/ICER_Obesity_Final-Report_For-Publication_121625-1.pdf); [Atlas et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10387935/); [Hwang et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11909610/); [Kim et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10372962/); [Johansson et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42012820/); [CBO (2024)](https://www.cbo.gov/publication/60441); [Ippolito and Levy (2024)](https://pubmed.ncbi.nlm.nih.gov/39146500/); [CMS Medicare GLP-1 Bridge (2026)](https://www.cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1-bridge); [KFF (2025)](https://www.kff.org/health-costs/2025-employer-health-benefits-survey/)

<a id="topic-4.1-2"></a>

#### Product-specific economic evaluation of VK2735

No evidence found.

<a id="topic-4.1-3"></a>

#### ICER model: structure, perspective, time horizon, and discounting

> “The primary aim of this analysis was to estimate the cost-effectiveness of three weight-lowering medications over a lifetime horizon. We developed a de novo decision analytic Markov cohort model for this evaluation, informed by key clinical trials and prior relevant economic models, with primary reference to ICER’s previously developed obesity model.”
> “Based on clinical evidence, expert opinion, and public comments, the model focused on the following obesity-related outcomes: T2D, CV disease and events, end-stage kidney disease (ESKD), cirrhosis, hip or knee replacement, and OSA.”
> “Analyses were conducted from the health sector perspective as a base case (i.e., focus on direct medical care costs only) and the modified societal perspective as a scenario analysis. Costs and outcomes are discounted at 3% per year.”

Source: [ICER (2025)](https://icer.org/wp-content/uploads/2025/12/ICER_Obesity_Final-Report_For-Publication_121625-1.pdf)

<a id="topic-4.1-4"></a>

#### ICER model: net prices used

> “In cost-effectiveness analyses, we used estimated net prices from SSR Health of $6,830 for injectable semaglutide and $7,973 for tirzepatide; we assumed the price of oral semaglutide was the same as injectable semaglutide.”

Source: [ICER (2025)](https://icer.org/wp-content/uploads/2025/12/ICER_Obesity_Final-Report_For-Publication_121625-1.pdf)

<a id="topic-4.1-5"></a>

#### ICER base case: incremental cost-effectiveness ratios versus lifestyle modification

| Treatment | Cost per QALY gained | Cost per evLY gained |
| --- | --- | --- |
| Injectable semaglutide | “$66,355” | “$65,280” |
| Oral semaglutide (placeholder price) | “$75,456” | “$74,143” |
| Tirzepatide | “$57,779” | “$57,188” |

Source: [ICER (2025)](https://icer.org/wp-content/uploads/2025/12/ICER_Obesity_Final-Report_For-Publication_121625-1.pdf)

> “All drugs were cost-effective at the $100,000 per QALY and evLY gained thresholds.”
> “The parameters with the greatest influence on the cost-effectiveness results across all three interventions were the treatment effect on BMI at year two and the quality-of-life change associated with BMI independent of modeled outcomes.”

Source: [ICER (2025)](https://icer.org/wp-content/uploads/2025/12/ICER_Obesity_Final-Report_For-Publication_121625-1.pdf)

<a id="topic-4.1-6"></a>

#### ICER health benefit price benchmarks based on QALYs gained

| Treatment | Annual net price | Annual price at $100,000 threshold | Annual price at $150,000 threshold |
| --- | --- | --- | --- |
| Injectable semaglutide | “$6,829” | “$9,100” | “$12,400” |
| Oral semaglutide | “$6,829” | “$8,300” | “$11,300” |
| Tirzepatide | “$7,973” | “$11,700” | “$15,900” |

Source: [ICER (2025)](https://icer.org/wp-content/uploads/2025/12/ICER_Obesity_Final-Report_For-Publication_121625-1.pdf)

> “The Health Benefit Price Benchmark (HBPB) for a drug is defined as the price range that would achieve incremental cost-effectiveness ratios between $100,000 per QALY and $150,000 per evLY gained. At the current net price – or the assumed net price in the case of oral semaglutide – we estimate no discounts are needed for any of the three drugs.”
> “The net price of oral semaglutide was assumed to equal that of injectable semaglutide.”

Source: [ICER (2025)](https://icer.org/wp-content/uploads/2025/12/ICER_Obesity_Final-Report_For-Publication_121625-1.pdf)

<a id="topic-4.1-7"></a>

#### ICER appraisal committee votes on long-term value for money

> “The council majority voted that injectable semaglutide, oral semaglutide, and tirzepatide offer high long-term value for money at the current or assumed pricing.”

Source: [ICER (2025)](https://icer.org/wp-content/uploads/2025/12/ICER_Obesity_Final-Report_For-Publication_121625-1.pdf)

<a id="topic-4.1-8"></a>

#### ICER potential budget impact: eligible population, uptake, and time horizon

> “All costs were undiscounted and estimated over a five-year time horizon.”
> “From this population, we excluded those who are already receiving medication treatment for obesity (22%).”
> “Applying these sources to the total US adult population averaged over the next five years (~270,900,000)”
> “results in estimates of ~92,000,000 eligible patients.”
> “We first conducted individual budget impact analyses for each intervention of interest (Figure 7.1), assuming that 20% of the eligible population would initiate the treatment in each of the five years, or ~18,400,000 patients per year.”

Source: [ICER (2025)](https://icer.org/wp-content/uploads/2025/12/ICER_Obesity_Final-Report_For-Publication_121625-1.pdf)

<a id="topic-4.1-9"></a>

#### ICER potential budget impact: annual budget impact per patient treated

> “At the injectable semaglutide net price of $6,829, the average annual budget impact per patient was $6,607 in year one, with cumulative annual budget impact per patient increasing to $16,426 by year five.”
> “At the tirzepatide net price of $7,973, the average annual budget impact per patient was $7,711 in year one, with cumulative annual budget impact per patient increasing to $19,439 by year five.”
> “At the net prices of each intervention of interest, the average annual budget impact per patient was $6,908 in year one, with cumulative annual budget impact per patient increasing to $17,422 by year five.”

Source: [ICER (2025)](https://icer.org/wp-content/uploads/2025/12/ICER_Obesity_Final-Report_For-Publication_121625-1.pdf)

<a id="topic-4.1-10"></a>

#### ICER access and affordability alert

> “At the current net prices of injectable semaglutide ($6,829 per year) and tirzepatide ($7,973 per year), and an assumed price of oral semaglutide ($6,829 per year), fewer than 1% of the US population eligible for the treatments (92 million) could be treated within five years without crossing ICER’s potential budget impact threshold of $880 million per year. Even assuming the new Medicare price for these interventions ($245 per month) applies to all eligible patients in the US, the proportion of eligible patients who could be treated before reaching ICER’s budget impact threshold remains below 1%.”

Source: [ICER (2025)](https://icer.org/wp-content/uploads/2025/12/ICER_Obesity_Final-Report_For-Publication_121625-1.pdf)

<a id="topic-4.1-11"></a>

#### ICER policy findings on utilization, persistence, and pricing of current and pipeline products

> “Fewer than one-quarter of people in the U.S. who may qualify for treatment with GLP-1 RAs report currently using the drugs in a recent survey, with the number dropping to less than 10% of people age 65 and older.”
> “Furthermore, persistence with therapy appears low, with fewer than two-thirds prescribed GLP-1 RA therapy still on it one year later.”
> “For existing GLP-1 RA manufacturers, and those with products in the pipeline, consider steep discounts to prices in exchange for higher volume.”
> “The manufacturers have demonstrated the ability to reduce prices even further with the recently announced negotiated price for Medicare for the lowest dose of semaglutide of $274/month, and the announcement from the Trump administration of $245/month pricing for both drugs for Medicare and Medicaid.”
> “Increase access and affordable coverage for obesity medications by addressing policy barriers (e.g., removing or revising federal laws prohibiting Medicare Part D coverage for weight loss drugs) and updating health insurance coverage in public programs.”

Source: [ICER (2025)](https://icer.org/wp-content/uploads/2025/12/ICER_Obesity_Final-Report_For-Publication_121625-1.pdf)

<a id="topic-4.1-12"></a>

#### Prior ICER assessment: incremental cost-effectiveness ratios at earlier net prices

| Treatment versus lifestyle modification | Cost per QALY gained, $ | Cost per evLY gained, $ |
| --- | --- | --- |
| Semaglutide | “237,000” | “234,000” |
| Liraglutide | “483,000” | “473,000” |
| Phentermine/topiramate | “8,000” | “7,000” |
| Bupropion/naltrexone | “123,000” | “121,000” |

Source: [Atlas et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10387935/)

> “At the current price net of rebates, the incremental cost-effectiveness ratio for semaglutide and liraglutide exceeded the commonly accepted thresholds (Table 3).”
> “For semaglutide, the panel members voted that its long-term value for money at its current pricing is low (11/15 votes) or intermediate (4/15 votes).”

Source: [Atlas et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10387935/)

<a id="topic-4.1-13"></a>

#### Lifetime microsimulation of four anti-obesity medications in U.S. adults

> “Data were included from the 2017-2020 National Health and Nutrition Examination Survey of 4823 individuals (representing 126 million eligible US adults) aged 20 to 79 years who would meet clinical trial inclusion criteria for antiobesity medications.”
> “Despite the largest incremental QALY gains of 0.35 for tirzepatide and 0.25 for semaglutide among all antiobesity medications, the incremental cost-effectiveness ratios were $197 023/QALY and 467 676/QALY, respectively. To reach the $100 000/QALY threshold, their prices would require additional discounts by 30.5% for tirzepatide and 81.9% for semaglutide from their current net prices.”
> “Naltrexone-bupropion was cost saving due to its lower cost and had an 89.1% probability of being cost-effective at $100 000/QALY, whereas phentermine-topiramate had a 23.5% probability of being cost-effective at $100 000/QALY.”

Source: [Hwang et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11909610/)

<a id="topic-4.1-14"></a>

#### Semaglutide 2.4 mg versus diet and exercise and other anti-obesity medications: U.S. third-party payer model

> “A cohort Markov model was constructed to compare semaglutide 2.4 mg with the following comparators: no treatment, diet and exercise (D&E), and 3 branded AOMs (liraglutide 3 mg, phentermine-topiramate, and naltrexone-bupropion).”
> “In the base-case analysis, treatment with semaglutide 2.4 mg was estimated to improve QALYs by 0.138 to 0.925 and incur higher costs by $3,254 to $25,086 over the 30-year time horizon vs comparators. Semaglutide 2.4 mg is cost-effective against all comparators at the prespecified WTP threshold, with the incremental cost per QALY gained ranging from $23,556 to $144,296 per QALY gained.”
> “In the sensitivity analysis, extended maximum treatment duration, types of subsequent treatment following therapy discontinuation, and weight-rebound rates were identified as key drivers for model results.”

Source: [Kim et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10372962/)

<a id="topic-4.1-15"></a>

#### Tirzepatide versus semaglutide from a head-to-head trial: U.S. societal perspective model

> “This study evaluated the cost-effectiveness (from the United States [US] societal perspective) of tirzepatide at its maximum-tolerated-dose (MTD) compared to semaglutide (MTD), both administered adjunct to a reduced-calorie diet and increased physical activity.”
> “Tirzepatide (MTD) was estimated to be less costly and more efficacious compared to semaglutide (MTD) with per patient cost savings of $41,688, 0.506 QALYs gained and positive iNHB of 0.784, indicating a net health benefit for tirzepatide.”

Source: [Johansson et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42012820/)

<a id="topic-4.1-16"></a>

#### Semaglutide and tirzepatide in knee osteoarthritis with obesity

> “Tirzepatide provided greater health benefits at lower costs than semaglutide and yielded a $57,400/QALY ICER vs. diet and exercise.”
> “Tirzepatide’s ICER was most sensitive to changes in medication costs, treatment efficacy, and cohort baseline BMI.”

Source: [Betensky et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13229537/)

<a id="topic-4.1-17"></a>

#### Medicare beneficiaries eligible for anti-obesity medication coverage through an additional indication

> “The study sample included 3,277 adults with overweight or obesity on Medicare with prescription coverage without Medigap, representing 25,397,971 adults. Among this population, 34.2% (95% CI, 32.0–36.5%) or 8.7 million people were eligible for AOMs through Medicare pre-March 2024. Post-March 2024, 46.4% (95% CI, 43.9–48.8) or 11.8 million people were eligible for AOMs through Medicare.”

Source: [Chetty et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12045892/)

<a id="topic-4.1-18"></a>

#### Semaglutide for secondary prevention of cardiovascular disease: lifetime cost-effectiveness and spending

> “The model incorporated annual semaglutide cost of $8604 (2023 US price net of rebates and discounts) and adopted a health-system perspective.”
> “Adding semaglutide to usual care in the estimated 4 million US adults without diabetes eligible for secondary prevention of CVD is projected to avert 358 400 MACE at a cost of $148 100 per QALY gained (95% uncertainty interval, $127 100-$173 400).”
> “Treatment with semaglutide was projected to increase annual health care spending by $23 billion. Semaglutide would be cost-effective at a threshold of $120 000 per QALY gained if the annual cost were lowered an additional 18% to $7055.”

Source: [Hennessy et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41637062/)

<a id="topic-4.1-19"></a>

#### Federal budgetary effects of authorizing Medicare coverage of anti-obesity medications

> “In this report, the Congressional Budget Office estimates the budgetary effects of an illustrative policy that would authorize Medicare to cover AOMs starting in January 2026.”
> “Authorizing coverage of AOMs in Medicare would increase federal spending, on net, by about $35 billion from 2026 to 2034. Total direct federal costs of covering AOMs would increase from $1.6 billion in 2026 to $7.1 billion in 2034. Relative to the direct costs of the medications, total savings from beneficiaries’ improved health would be small—less than $50 million in 2026 and rising to $1.0 billion in 2034.”
> “Per AOM user, the average direct federal cost would be roughly $5,600 in 2026, decreasing to $4,300 in 2034. And average offsetting federal savings would be about $50 in 2026, reaching $650 in 2034.”
> “Over 12.5 million Medicare beneficiaries would newly qualify for AOMs in 2026 under the illustrative policy; 0.3 million, or 2 percent of the newly eligible population, would use an AOM in 2026.”
> “In that year, about 1.6 million (or 14 percent) of the newly eligible beneficiaries would use an AOM.”

Source: [CBO (2024)](https://www.cbo.gov/publication/60441)

<a id="topic-4.1-20"></a>

#### Estimated Medicare Part D spending if anti-obesity medications were covered

> “Assuming that anti-obesity drugs were covered in 2025 and that 5 percent or 10 percent of newly eligible patients were prescribed one, annual Part D costs were estimated to increase by $3.1 billion or $6.1 billion, respectively.”
> “Longer-term estimates come with significant uncertainty about utilization and price changes, but these results are consistent with this policy change likely increasing Medicare costs by the low to middle tens of billions of dollars over ten years.”

Source: [Ippolito and Levy (2024)](https://pubmed.ncbi.nlm.nih.gov/39146500/)

<a id="topic-4.1-21"></a>

#### Medicare GLP-1 Bridge demonstration: period and beneficiary copay

> “The Medicare GLP-1 Bridge is a short-term demonstration run by CMS that will provide eligible Medicare Part D beneficiaries with access to certain GLP-1 drugs between July 1, 2026, and December 31, 2027.”
> “The Medicare GLP-1 Bridge will operate outside of the Medicare Part D benefit’s coverage and payment flow. As a result, Part D sponsors will not carry risk for eligible GLP-1 drugs furnished under the Medicare GLP-1 Bridge”
> “Eligible beneficiaries will have a $50 copay.”

Source: [CMS Medicare GLP-1 Bridge (2026)](https://www.cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1-bridge)

<a id="topic-4.1-22"></a>

#### Employer coverage of GLP-1 agonists for weight loss

> “Among firms that offer health benefits with 200 or more workers, 16% of firms with 200 to 999 workers, 30% of firms with 1,000 to 4,999 workers, and 43% of firms with 5,000 or more workers cover GLP-1 agonists when used primarily for weight loss [Figure 13.16].”
> “The overall percentage of firms with 200 or more workers that cover GLP-1 agonists for weight loss (19%) is similar to the percentage last year (18%).”
> “Thirty-four percent of firms with 200 or more workers that cover GLP-1 agonists for weight loss require enrollees to meet with a dietitian, case manager, or therapist, or participate in a lifestyle program in order for the drug to be covered.”

Source: [KFF (2025)](https://www.kff.org/health-costs/2025-employer-health-benefits-survey/)

<a id="heading-4.2"></a>

### 4.2 Budget Impact Model

<a id="heading-4.2.1"></a>

#### 4.2.1 Approach and Framework

No evidence found.

<a id="heading-4.2.2"></a>

#### 4.2.2 Perspective and Time Frame

No evidence found.

<a id="heading-4.2.3"></a>

#### 4.2.3 Epidemiology and Eligible Population Inputs

No evidence found.

<a id="heading-4.2.4"></a>

#### 4.2.4 Cost Assumptions

No evidence found.

<a id="heading-4.2.5"></a>

#### 4.2.5 Model Outcomes

No evidence found.

<a id="heading-4.2.6"></a>

#### 4.2.6 Results

<a id="heading-4.2.6.1"></a>

##### 4.2.6.1 Base Case

No evidence found.

<a id="heading-4.2.6.2"></a>

##### 4.2.6.2 Scenario Analyses

No evidence found.

<a id="heading-4.2.7"></a>

#### 4.2.7 Budget impact model discussion

No evidence found.

## Related pages
- [VK2735: Chronic weight management](https://www.evicenter.com/drugs/vk2735--chronic-weight-management) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management.md)
- [VK2735 in Chronic weight management: Terms and abbreviations](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/terms-and-abbreviations.md)
- [VK2735: Chronic weight management](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/executive-summary) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/executive-summary.md)
- [VK2735 in Chronic weight management: Product information and disease description](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/product-information-and-disease-description.md)
- [VK2735 in Chronic weight management: Clinical evidence](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/clinical-evidence.md)
- [VK2735 in Chronic weight management: References](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/references) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/references.md)
